AB0345 Clinical Evaluation of Anti-Aminoacyl T-Rna Synthetase Antibody in Rheumatoid Arthritis Patients. (10th June 2014)

• Record Type: Journal Article
• Authors: Matsushita, M.; Kawamoto, T.; Yamaji, K.; Tamura, N.; Takasaki, Y.
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 918
• Page End: 918
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.1734
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: Anti-Jo-1 antibody is an autoantibody specifically detected in the serum of patients with polymyositis (PM) or dermatomyositis (DM). The homologous antigen of anti-Jo-1 antibody is a histidyl tRNA synthetase, one of the aminoacyl tRNA synthetases (ARS) found in cytoplasm. A number of antibodies homologous to other ARSs have been identified recently. Lung and skin diseases observed characteristically in patients with anti-Jo-1 antibody are collectively called anti-ARS antibody syndrome. We measured the anti-ARS antibody level in rheumatoid arthritis (RA) patients and evaluated the clinical characteristics of their symptoms. Methods: This study included 234 RA outpatients treated at our clinic to evaluate their anti-ARS antibody level, antinuclear antibody prevalence and staining pattern, concurrent interstitial pneumonia (IP), joint symptoms and Raynaud's phenomenon, concurrent PM/DM, and medications including biological drugs. The anti-ARS antibody level was measured using Myositis Profile 3 EUROLINE (EUROIMMUNE, Lubeck, Germany) according to the manufactures instructions. Results: Anti-ARS antibodies were detected in 18 patients (7.7%). Specifically, anti-PL-7 antibody was detected in 7 patients (3.0%), anti-EJ antibody was detected in 6 patients (2.6%), anti-Jo-1 antibody was detected in 2 patient (0.9%), anti-PL-12 antibody was detected in 2 patients (0.9%), and anti-OJ antibody was detected in 1 patient (0.4%). The evaluation of clinical characteristics found concurrent IP in 42.8% of anti-EJ antibody-positive patients, no anti-OJ antibody-positive patients, 71.4% of anti-PL-7 antibody-positive patients, and all anti-PL-12 antibody-positive patients. The results suggest anti-PL-12 antibody and anti-PL-7 antibody are IP-related autoantibodies. In patients with concurrent IP, the prevalence was significantly high (33.3%). The evaluation of non-IP clinical presentations in anti-ARS antibody positive patients found no noteworthy characteristics such as arthritis, skin symptoms, and use of specific medications. Biological drugs were used in 3 anti-ARS antibody-positive patients safely without inducing myositis or aggravating IP. Conclusions: Of the anti-ARS antibodies specifically detected in PM/DM patients, anti-PL-7 and anti-PL-12 antibodies were detected in RA patients with concurrent IP at a significantly high frequency, suggesting these autoantibodies are associated with IP. Biological drugs may be used safely in patients tested positive for these autoantibodies. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.1734